CD59 as a modulator of T cell activity in vivo. (360G-Wellcome-079115_Z_06_Z)

£168,228

Identification of molecules that influence T cell activation either positively or negatively will facilitate manipulation of T cell responses in order to amplify those that are beneficial and to inhibit those that are harmful. Preliminary experiments indicate that a complement regulator protein, CD59, downmodulates T cell activity in mice. Mice lacking CD59 show enhanced antiviral CD4+ T cell responses and an enhanced ability to clear virus infections. These studies have led us to hypothesise that lack of CD59 expression on T cells 1) exacerbates virus-induced immunopathology and 2) promotes anti-tumour immunity. The first hypothesis will be tested by comparing virus-specific immune responses and pathology in influenza-infected CD59-deficient and CD59-sufficient mice. In a separate set of experiments we will address whether CD59 expression on T cells limits their anti-tumour potential. Using tumour models already established within the laboratory, we will address whether a) CD59-deficient T cells are more effective than CD59-sufficient T cells at tumour rejection and b) whether silencing of CD59 using siRNA technology enhances the anti-tumour capacity of T cells isolated from CD59-sufficient mice. Lastly, a phenotypic and functional analysis of CD59 expression in human T cell activities in vitro will be undertaken.

Where is this data from?

This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.

Grant Details

Amount Awarded 168228
Applicant Surname Gallimore
Approval Committee Immunology and Infectious Disease Funding Committee
Award Date 2006-02-09T00:00:00+00:00
Financial Year 2005/06
Grant Programme: Title Project Grant
Internal ID 079115/Z/06/Z
Lead Applicant Prof Awen Gallimore
Other Applicant(s) Prof Paul Morgan
Partnership Value 168228
Planned Dates: End Date 2008-09-30T00:00:00+00:00
Planned Dates: Start Date 2006-06-01T00:00:00+00:00
Recipient Org: Country United Kingdom
Region Wales